Orthopedics This Week
Subscribe today to listen to this content Get Access
Ready for SuperBall in Rotator Cuff treatment? Arcuro Medical, Ltd. has expanded its SuperBall platform to include rotator cuff repair, building on the experience of its SuperBall-MR meniscal repair system. Subscribe to continue reading
Exclusive access to our newsletter
Join the Conversation! Exclusive access to article comments. $24.99/month

Suture Meets Superpowers: A New Chapter in Shoulder and Knee Repair

Arcuro Medical Significantly Expands SuperBall® Market Opportunity with New Rotator Cuff Repair System; Launches Newly-Enhanced Meniscus Repair System
New indications and enhancements target a potential $1.1 billion addressable market by 2028
17 February 2026
Medtech
Arcuro Medical, Ltd. (“Arcuro” ) announced its first cases of the new SuperBall®-RC (Rotator Cuff Repair System), an enhanced iteration of the SuperBall®-MR (Meniscal Repair System), and newly published white papers summarizing data supporting both technologies. Rotator Cuff Indication Significantly Expands Addressable Market
The SuperBall-RC offers an all-suture, knotless solution for arthroscopic medial rotator cuff augmentation, with a mesh construct to minimize potential damage to tissue and avoid potential complications of alternative hard polymer staple technologies. Following U.S. regulatory clearance in early 2025, Arcuro initiated a limited user release of the SuperBall-RC primarily addressing patch-augmented rotator cuff repair and other challenging rotator cuff procedures. Early cases have been successfully completed using a range of commercially available biologic and synthetic patches. The Company estimates SuperBall-RC procedures will have a global addressable market opportunity of $389 million by 2028, growing in low double-digits through the end of the decade. Surgeon-led design improvements reinforce optimal strength, reproducibility, and all-inside efficiency in meniscal preservation
The SuperBall-MR was engineered to deliver reliable, consistent meniscal repair constructs through a streamlined all-inside, all-suture technique. The latest enhancements introduced in mid-2025 based on surgeon feedback build upon its proprietary platform to further optimize deployment performance, construct strength, and procedural reproducibility. The Company estimates approximately 7,000 SuperBall procedures have now been performed across meniscus repair applications, with an estimated 700 procedures successfully completed using the upgraded system. The Company estimates the global addressable market opportunity for SuperBall-MR is $705 million by 2028, also growing in low double-digits through the end of the decade. New Clinical and Biomechanical Publications
Arcuro released new white papers summarizing SuperBall-MR post-market clinical experience and preclinical SuperBall-RC data. A multi-center post-market SuperBall-MR evaluation of 140 patients reported a 98.6% deployment success rate, no device-related complications, and no revision surgeries in early follow-up. An interim SuperBall-MR post-market surveillance report similarly reported no adverse events and demonstrated continued functional improvement in evaluated patients. Finally, biomechanical testing of SuperBall-RC demonstrated fixation strength comparable to or greater than traditional hard polymer staples, with substantially higher individual implant pullout strength. New technologies for Rotator Cuff augmentation may offer significant benefits for patients that are at risk for failure to heal with rotator cuff surgery. However, securing tissue patch grafts and augmentation implants arthroscopically can be challenging. The SuperBall-RC offers a straightforward all-suture fixation solution compatible with a wide range of patch devices and is an important complement to these cases. In addition it can be used for side-to-side tissue repair and securing cuff tissue to long head biceps based rotator cuff reconstructions, offering a versatile, efficient, and biomechanically robust option to enable these cases. Dr. Theodore Shybut, Orthopedic & Sports Medicine surgeon at the Southern California Orthopedic Institute – a UCLA Health affiliate
Successful meniscal healing depends on stable fixation, compression, and consistent deployment. The SuperBall-MR system addresses these fundamentals through its all-suture, knotless mesh construct while avoiding rigid anchors. The recent enhancements reflect strong collaboration between surgeons and Arcuro’s development team and meaningfully improves real-world consistency in challenging cases and our overall surgical workflow. Dr. Robert Meislin, Orthopedic & Sports Medicine surgeon at NYU Langone Health, New York. See More News

Arcuro Medical Significantly Expands SuperBall® Market Opportunity with New Rotator Cuff Repair System; Launches Newly-Enhanced Meniscus Repair System

Arcuro Medical Significantly Expands SuperBall® Market Opportunity with New Rotator Cuff Repair System; Launches Newly-Enhanced Meniscus Repair System
Courtesy of Arcuro Medical, Ltd
MINNEAPOLIS and MISGAV, Israel, Feb. 17, 2026 /PRNewswire/ — Arcuro Medical, Ltd. (“Arcuro” or “Company”) today announced its first cases of the new SuperBall®-RC (Rotator Cuff Repair System), an enhanced iteration of the SuperBall®-MR (Meniscal Repair System), and newly published white papers summarizing data supporting both technologies. Rotator Cuff Indication Significantly Expands Addressable Market
The SuperBall-RC offers an all-suture, knotless solution for arthroscopic medial rotator cuff augmentation, with a mesh construct to minimize potential damage to tissue and avoid potential complications of alternative hard polymer staple technologies. Following U.S. regulatory clearance in early 2025, Arcuro initiated a limited user release of the SuperBall-RC primarily addressing patch-augmented rotator cuff repair and other challenging rotator cuff procedures. Early cases have been successfully completed using a range of commercially available biologic and synthetic patches. The Company estimates SuperBall-RC procedures will have a global addressable market opportunity of $389 million by 2028, growing in low double-digits through the end of the decade. “New technologies for Rotator Cuff augmentation may offer significant benefits for patients that are at risk for failure to heal with rotator cuff surgery,” said Dr. Theodore Shybut, Orthopedic & Sports Medicine surgeon at the Southern California Orthopedic Institute – a UCLA Health affiliate. “However, securing tissue patch grafts and augmentation implants arthroscopically can be challenging. The SuperBall-RC offers a straightforward all-suture fixation solution compatible with a wide range of patch devices and is an important complement to these cases. In addition, it can be used for side-to-side tissue repair and securing cuff tissue to long head biceps-based rotator cuff reconstructions, offering a versatile, efficient, and biomechanically robust option to enable these cases.”
Surgeon-led design improvements reinforce optimal strength, reproducibility, and all-inside efficiency in meniscal preservation. The SuperBall-MR was engineered to deliver reliable, consistent meniscal repair constructs through a streamlined all-inside, all-suture technique. The latest enhancements introduced in mid-2025 based on surgeon feedback build upon its proprietary platform to further optimize deployment performance, construct strength, and procedural reproducibility. The Company estimates approximately 7,000 SuperBall procedures have now been performed across meniscus repair applications, with an estimated 700 procedures successfully completed using the upgraded system. The Company estimates the global addressable market opportunity for SuperBall-MR is $705 million by 2028, also growing in low double-digits through the end of the decade. “Successful meniscal healing depends on stable fixation, compression, and consistent deployment,” said Dr. Robert Meislin, Orthopedic & Sports Medicine surgeon at NYU Langone Health, New York. “The SuperBall-MR system addresses these fundamentals through its all-suture, knotless mesh construct while avoiding rigid anchors. The recent enhancements reflect strong collaboration between surgeons and Arcuro’s development team and meaningfully improves real-world consistency in challenging cases and our overall surgical workflow.”
New Clinical and Biomechanical Publications
Arcuro released new white papers summarizing SuperBall-MR post-market clinical experience and preclinical SuperBall-RC data. A multi-center post-market SuperBall-MR evaluation of 140 patients reported a 98.6% deployment success rate, no device-related complications, and no revision surgeries in early follow-up. An interim SuperBall-MR post-market surveillance report similarly reported no adverse events and demonstrated continued functional improvement in evaluated patients. Finally, biomechanical testing of SuperBall-RC demonstrated fixation strength comparable to or greater than traditional hard polymer staples, with substantially higher individual implant pullout strength. Investor Conference and New Website
Arcuro also launched a redesigned corporate website featuring expanded clinical resources and access to its latest publications. Management will present a business and clinical update at the Canaccord Genuity Musculoskeletal Conference in New Orleans on March 2, 2026. About Arcuro Medical Ltd.
Arcuro Medical Ltd. develops advanced all-suture technologies designed to improve soft-tissue repair and joint preservation. Its flagship platform, the SuperBall System, provides strong, knotless fixation with controlled tensioning and a proprietary mesh construct that reduces tissue damage and enhances surgical outcomes. With regulatory clearances in the U.S. and international markets, Arcuro is enabling surgeons around the world to repair tissue more reliably and preserve natural joint function. Founded in 2014 and led by a team with decades of experience in sports medicine, product development, and commercialization, Arcuro has helped thousands of patients and continues to invest in clinical evidence and next-generation innovations. For more information on Arcuro and its products, visit  arcuromedical.com  and follow the company on  LinkedIn . Contact information:

Rotator Cuff Injuries Market Report
The rotator cuff injuries treatment market is expected to witness substantial growth, primarily fueled by an increasing prevalence, an aging population, advancements in minimally invasive surgical techniques, and the emergence of novel biologic therapies. Key rotator cuff repair companies, including Ortho Regenerative Technologies, Angiocrine Bioscience, Smith & Nephew, Arcuro Medical, and Atreon Orthopedics, are at the forefront of innovation, addressing the significant unmet needs. DelveInsight’s “ Rotator Cuff Injuries Market Insights, Epidemiology, and Market Forecast 2032 ” report delivers an in-depth understanding of rotator cuff injuries treatment market, historical and forecasted epidemiology, as well as rotator cuff injury treatment market forecast across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. The report provides valuable insights into current treatment practices, rotator cuff injuries, emerging therapies, market share of individual treatments, and projected market size till 2032, offering a comprehensive picture of this evolving therapeutic landscape. The rotator cuff syndrome market is experiencing notable growth, shaped by several converging trends. The rising incidence of shoulder injuries, particularly among athletes and the aging population, remains a primary driver. Regionally, the US dominates the market among 7MM, benefiting from a robust healthcare infrastructure, favorable reimbursement policies, and a high prevalence of sports-related injuries
Download the rotator cuff injuries market report to understand which factors are driving the rotator cuff injuries therapeutic market @ Rotator Cuff Injuries Market Trends . Rotator cuff injuries represent one of the most common musculoskeletal disorders worldwide, with millions of individuals affected globally. According to epidemiological data cited in the report, the rotator cuff syndrome prevalence varies significantly by age, ranging from 5-10% in patients under 20 years to over 60% in individuals aged 80 and above. A prospective German population study revealed a 23% overall prevalence of rotator cuff tears, with rates increasing to 31% in those aged 70 and 51% in those aged 80, highlighting the strong correlation between advancing age and rotator cuff pathology. Additional risk factors include repetitive overhead activities, smoking, hypercholesterolemia, and genetic predisposition, all contributing to the progressive degeneration of tendon tissue. Discover evolving trends in the rotator cuff injuries patient pool forecasts @ Rotator Cuff Injuries Epidemiology Analysis . The current treatment paradigm for rotator cuff injuries follows a stepwise approach, beginning with conservative management including rest, physical therapy, and over-the-counter pain relievers such as ibuprofen and acetaminophen. When these interventions fail to provide adequate relief, physicians may administer steroid injections, though these are used judiciously due to the potential long-term weakening of tendon tissue, emphasising the rotator cuff injuries market challenges. For severe or non-responsive cases, surgical intervention becomes necessary, with options including arthroscopic tendon repair, open tendon repair, tendon transfer, and shoulder replacement for massive, irreparable tears—a factor that also significantly influences the shoulder replacement market as demand rises for advanced surgical solutions. The rotator cuff injury treatment landscape is witnessing significant innovation, with several promising therapies in various stages of clinical development. Ortho-R/PRP, developed by Ortho Regenerative Technologies, is currently in Phase I/II trials and represents an advanced freeze-dried chitosan-platelet-rich plasma hybrid formulation designed to augment healing rates of sports and occupational injuries. The proprietary biopolymer matrix serves as a biodegradable scaffold, increasing the residency time of PRP components at the surgical site and enhancing therapeutic efficacy through the prolonged release of growth factors. Another noteworthy candidate is E-CEL UVEC (AB-207) from Angiocrine Bioscience, an investigational cell therapy consisting of genetically modified endothelial cells derived from human umbilical cord blood vessels. This innovative approach has demonstrated accelerated healing and increased strength at the tendon-bone interface in preclinical studies and is currently progressing through Phase Ib/II clinical evaluation after receiving Investigational New Drug status from the FDA. In a significant development in February 2025, Atreon Orthopedics received clearance for its BioCharge Autobiologic Matrix, which is designed to enhance the integrity of rotator cuff repairs and improve long-term patient outcomes. Additionally, Arcuro Medical’s SuperBall-RC system, an innovative device aimed at addressing the high re-tear rates, ranging from 20% to 40% in patients over 50, also received clearance in February 2025. This system simplifies the fixation of augmentation grafts, a process that has traditionally been technically demanding with existing surgical techniques. The BioCharge Autobiologic Matrix further expands the range of advanced biological solutions available to orthopedic surgeons. Following its expedited FDA clearance, Arcuro Medical plans a limited user release in the second quarter of 2025. Additionally, in February 2025, ZuriMED Technologies AG announced that its FiberLocker System received FDA 510(k) clearance. This marks a significant milestone for the company and advances the technology for rotator cuff repairs. This FDA clearance is the result of years of dedicated development and collaboration, positioning ZuriMED to make a meaningful impact in the field of orthopedic soft tissue repair. Furthermore, in December 2024, the Zimmer Biomet OsseoFit Stemless Shoulder System received FDA 510(k) clearance for total shoulder replacement. This anatomically shaped, stemless design aims to optimize bone preservation and fixation, especially important for younger and more active patients. The system was expected to be commercially available in Q1 2025. The market also features established products such as Smith & Nephew’s REGENETEN Bioinductive Implant, composed of type 1 collagen, which stimulates the body’s natural healing response to induce new tendon-like tissue growth and disrupt disease progression across the entire spectrum of rotator cuff tears. Looking ahead, the rotator cuff injuries market is expected to undergo significant transformation. The integration of regenerative medicine approaches, coupled with advances in surgical techniques and imaging modalities, promises to improve outcomes and reduce recovery times for patients suffering from these debilitating injuries. DelveInsight’s comprehensive analysis provides valuable insights for stakeholders in the rotator cuff treatment landscape, including detailed patient-based market forecasting, therapeutic approaches, pipeline analysis, market opportunities, and the impact of upcoming therapies. The rotator cuff repair market forecast across seven major markets, combined with in-depth epidemiological segmentation and competitive analysis, offers an essential resource for understanding the evolving dynamics of this important orthopedic condition. Table of Contents

Rotator Cuff Injuries Market Poised for Significant Growth by 2032, Driven by Innovative Biologics and Regenerative Therapies | DelveInsight

Arcuro Medical Announces FDA 510(k) Clearance for the SuperBall RC for Rotator Cuff Indications
27 February 2025
Medtech
Arcuro Medical Ltd. , (“Arcuro”) today announced that it received FDA 510(k) clearance for its new SuperBall-RC™ system for use in rotator cuff repair procedures. Current rotator cuff re-tear rates following surgery can range from 20%-40% in patients over 50. [1] Rotator cuff augmentation with biologic or biosynthetic grafts can mitigate this risk but can be technically demanding with current surgical techniques. The new SuperBall-RC product, based on Arcuro’s SuperBall technology platform successfully used in over 5,000 meniscus repairs, addresses this unmet need. The SuperBall-RC will enter a limited user release in the second quarter of 2025 in anticipation of a full launch in the second half of 2025, ahead of schedule due to the timely FDA clearance. [1] Routledge et al. Re-Tear Rates Following Rotator Cuff Repair Surgery. Cureus. 2023 Jan 31;15(1)
The SuperBall-RC has been designed to facilitate safe and easy fixation of rotator cuff augmentation grafts. The device has exceeded my expectations and offers a very attractive alternative to fixate augmentation patches and enhance healing. Philip Davidson, MD, Arcuro’s Medical Director
We are thrilled to have received this regulatory clearance, and I congratulate our product development and regulatory teams for their excellent work on this important milestone for the company which will help surgeons facilitate improved rotator cuff repair outcomes for their patients. Jamal Rushdy, Arcuro’s CEO
See More News

Arcuro Medical Announces FDA 510(k) Clearance for the SuperBall RC for Rotator Cuff Indications

WIBERG

Series A

Arcuro Medical produces orthopedic medical devices that focus on soft-tissue repair in the healthcare sector. The company offers the SuperBall4 Meniscal Repair System, an all-suture platform for meniscal and rotator cuff procedures that allows for tensioning and fixation for soft-tissue repairs. Arcuro Medical's products are used by healthcare professionals in orthopedic surgery. It was founded in 2013 and is based in Misgav, Israel.

Date	1/6/2025
Round	Series A
Amount
Investors	Varana Capital, The Trendlines Group, and Undisclosed Investors
Valuation	$XXM
Revenue	0 FY undefined
Sources	2

First funding	Last Funding	Investor	Rounds	Board Seats	Type	Location
1/6/2025	1/6/2025	The Trendlines Group	1 Series A		Venture Capital	Israel
00/00/0000	00/00/0000	Varana Capital	Subscribe to see more		Asset/Investment Management	New York

First funding	1/6/2025	00/00/0000
Last Funding	1/6/2025	00/00/0000
Investor	The Trendlines Group	Varana Capital
Rounds	1 Series A	Subscribe to see more
Board Seats
Type	Venture Capital	Asset/Investment Management
Location	Israel	New York

How VCs Use CB Insights

Professional Services

Platform Overview

Arcuro Medical

Investors Count

Funding, Valuation & Revenue

Arcuro Medical Investors